These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Interstitial fibrosis and tubular atrophy in renal allograft protocol biopsies as a surrogate of graft survival.
    Author: Serón D.
    Journal: Transplant Proc; 2009 Mar; 41(2):769-70. PubMed ID: 19328976.
    Abstract:
    Interstitial fibrosis and tubular atrophy (IF/TA) evaluated in protocol renal allograft biopsies are associated with decreased graft survival, especially when associated with transplant vasculopathy, subclinical rejection, or transplant glomerulopathy. IF/TA evaluated in protocol biopsies has been used as a secondary efficacy variable in clinical trials, some of which have shown that the prevalence of IF/TA depends on the type of immunosuppressive treatment. These observations suggest that IF/TA may be considered a surrogate of graft survival. However, there is an important difference between a predictive and a surrogate variable. A predictive variable is associated only with the main outcome variable, whereas in case of a surrogate variable, an additional condition must be accomplished; that is, modifications of the predictive variable as a result of treatment imply changes in the main outcome variable. In a trial of cyclosporine withdrawal from a cyclosporine-sirolimus-prednisone regimen, cyclosporine discontinuation was associated with less severe chronic lesions in protocol biopsies at 3 years and also with improved graft survival at 4 years. This observation suggest that IF/TA may be a surrogate of survival. This conclusion must be confirmed in other trials before accepting IF/TA as a real surrogate of graft outcome.
    [Abstract] [Full Text] [Related] [New Search]